SE0201658D0 - Immediate release pharmaceutical formulation - Google Patents

Immediate release pharmaceutical formulation

Info

Publication number
SE0201658D0
SE0201658D0 SE0201658A SE0201658A SE0201658D0 SE 0201658 D0 SE0201658 D0 SE 0201658D0 SE 0201658 A SE0201658 A SE 0201658A SE 0201658 A SE0201658 A SE 0201658A SE 0201658 D0 SE0201658 D0 SE 0201658D0
Authority
SE
Sweden
Prior art keywords
active ingredient
sup
immediate release
pharmaceutical formulation
solution
Prior art date
Application number
SE0201658A
Other languages
English (en)
Swedish (sv)
Inventor
Alami Susanna Abrahamsen
Tord Inghardt
Anders Magnusson
Carl-Gustaf Sigfridsson
Mikael Thune
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0201658(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201658A priority Critical patent/SE0201658D0/xx
Publication of SE0201658D0 publication Critical patent/SE0201658D0/xx
Priority to CA002485533A priority patent/CA2485533A1/fr
Priority to JP2004508781A priority patent/JP4537197B2/ja
Priority to BR0311363-9A priority patent/BR0311363A/pt
Priority to SG2006083430A priority patent/SG172473A1/en
Priority to AU2003241239A priority patent/AU2003241239B2/en
Priority to UA20041109446A priority patent/UA82191C2/uk
Priority to CNA038124904A priority patent/CN1655760A/zh
Priority to IL16506903A priority patent/IL165069A0/xx
Priority to NZ536739A priority patent/NZ536739A/en
Priority to EP03730964A priority patent/EP1513496A1/fr
Priority to NZ549273A priority patent/NZ549273A/en
Priority to MXPA04011943A priority patent/MXPA04011943A/es
Priority to RU2004133387/15A priority patent/RU2351314C2/ru
Priority to PCT/SE2003/000857 priority patent/WO2003101423A1/fr
Priority to PL03373908A priority patent/PL373908A1/xx
Priority to US10/516,423 priority patent/US20060014734A1/en
Priority to KR10-2004-7019465A priority patent/KR20050010016A/ko
Priority to TW096117054A priority patent/TW200735864A/zh
Priority to TW092114804A priority patent/TWI311555B/zh
Priority to ARP030101933A priority patent/AR039935A1/es
Priority to SA03240403A priority patent/SA03240403B1/ar
Priority to NO20044810A priority patent/NO20044810L/no
Priority to ZA200409237A priority patent/ZA200409237B/en
Priority to IS7582A priority patent/IS7582A/is
Priority to RU2008141850/15A priority patent/RU2008141850A/ru
Priority to CL2008003324A priority patent/CL2008003324A1/es
Priority to AU2010200821A priority patent/AU2010200821A1/en
Priority to JP2010100905A priority patent/JP2010209090A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0201658A 2002-05-31 2002-05-31 Immediate release pharmaceutical formulation SE0201658D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE0201658A SE0201658D0 (sv) 2002-05-31 2002-05-31 Immediate release pharmaceutical formulation
US10/516,423 US20060014734A1 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
KR10-2004-7019465A KR20050010016A (ko) 2002-05-31 2003-05-27 즉시 방출형 약학 제형
RU2004133387/15A RU2351314C2 (ru) 2002-05-31 2003-05-27 Фармацевтический препарат с немедленным высвобождением
PCT/SE2003/000857 WO2003101423A1 (fr) 2002-05-31 2003-05-27 Formulation pharmaceutique a liberation immediate
BR0311363-9A BR0311363A (pt) 2002-05-31 2003-05-27 Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
SG2006083430A SG172473A1 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
AU2003241239A AU2003241239B2 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
UA20041109446A UA82191C2 (uk) 2002-05-31 2003-05-27 Фармацевтична таблеткова композиція негайного вивільнення
CNA038124904A CN1655760A (zh) 2002-05-31 2003-05-27 速释药物制剂
IL16506903A IL165069A0 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
NZ536739A NZ536739A (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
EP03730964A EP1513496A1 (fr) 2002-05-31 2003-05-27 Formulation pharmaceutique a liberation immediate
NZ549273A NZ549273A (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
MXPA04011943A MXPA04011943A (es) 2002-05-31 2003-05-27 Formulacion farmaceutica de liberacion inmediata.
CA002485533A CA2485533A1 (fr) 2002-05-31 2003-05-27 Formulation pharmaceutique a liberation immediate
JP2004508781A JP4537197B2 (ja) 2002-05-31 2003-05-27 即時放出性医薬製剤
PL03373908A PL373908A1 (en) 2002-05-31 2003-05-27 Immediate release pharmaceutical formulation
ARP030101933A AR039935A1 (es) 2002-05-31 2003-05-30 Formulacion farmaceutica de liberacion inmediata
TW092114804A TWI311555B (en) 2002-05-31 2003-05-30 Immediate release pharmaceutical formulation
TW096117054A TW200735864A (en) 2002-05-31 2003-05-30 Immediate release pharmaceutical formulation
SA03240403A SA03240403B1 (ar) 2002-05-31 2003-11-30 تصنيع املاح حمض سيلفونيك ذات انبعاث فوري واستخدامها في علاج الاضطرابات القلبية الوعائية
NO20044810A NO20044810L (no) 2002-05-31 2004-11-04 Farmasoytisk formulering med oyeblikkelig frigjoring
ZA200409237A ZA200409237B (en) 2002-05-31 2004-11-17 Immediate release pharmaceutical formulation.
IS7582A IS7582A (is) 2002-05-31 2004-12-03 Hraðlosandi lyfjablanda
RU2008141850/15A RU2008141850A (ru) 2002-05-31 2008-10-23 Жидкий фармацевтический препарат с немедленным высвобождением
CL2008003324A CL2008003324A1 (es) 2002-05-31 2008-11-07 Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
AU2010200821A AU2010200821A1 (en) 2002-05-31 2010-03-03 Immediate release pharmaceutical formulation
JP2010100905A JP2010209090A (ja) 2002-05-31 2010-04-26 即時放出性医薬製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201658A SE0201658D0 (sv) 2002-05-31 2002-05-31 Immediate release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0201658D0 true SE0201658D0 (sv) 2002-05-31

Family

ID=20288036

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201658A SE0201658D0 (sv) 2002-05-31 2002-05-31 Immediate release pharmaceutical formulation

Country Status (24)

Country Link
US (1) US20060014734A1 (fr)
EP (1) EP1513496A1 (fr)
JP (2) JP4537197B2 (fr)
KR (1) KR20050010016A (fr)
CN (1) CN1655760A (fr)
AR (1) AR039935A1 (fr)
AU (2) AU2003241239B2 (fr)
BR (1) BR0311363A (fr)
CA (1) CA2485533A1 (fr)
CL (1) CL2008003324A1 (fr)
IL (1) IL165069A0 (fr)
IS (1) IS7582A (fr)
MX (1) MXPA04011943A (fr)
NO (1) NO20044810L (fr)
NZ (1) NZ536739A (fr)
PL (1) PL373908A1 (fr)
RU (2) RU2351314C2 (fr)
SA (1) SA03240403B1 (fr)
SE (1) SE0201658D0 (fr)
SG (1) SG172473A1 (fr)
TW (2) TWI311555B (fr)
UA (1) UA82191C2 (fr)
WO (1) WO2003101423A1 (fr)
ZA (1) ZA200409237B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
CN101528215B (zh) * 2006-10-20 2011-10-19 艾科斯有限公司 Chk1抑制剂和环糊精的组合物
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
US9927801B2 (en) 2012-05-11 2018-03-27 D.P. Technology Corp. Automatic method for milling complex channel-shaped cavities via coupling flank-milling positions
US8977382B2 (en) * 2012-05-11 2015-03-10 D.P. Technology Corp. Automatic method for milling complex channel-shaped cavities
CN102827053A (zh) * 2012-09-20 2012-12-19 天津嘉宏科技有限公司 芳族脒衍生物，其制备方法及作为药物的用途
NZ727818A (en) 2014-06-03 2020-06-26 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
SG11201701998XA (en) 2014-09-15 2017-04-27 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
ES2971626T3 (es) 2017-02-06 2024-06-06 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la síntesis de 1-aril-1-trifluorometilciclopropanos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252566A (en) * 1991-11-12 1993-10-12 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CA2345641A1 (fr) * 1998-09-28 2000-04-06 Merck & Co., Inc. Procede de traitement de maladies inflammatoires par administration d'un inhibiteur de la thrombine
WO2000042059A1 (fr) * 1999-01-13 2000-07-20 Astrazeneca Ab Nouveaux derives d'amidinobenzylamine et leur utilisation comme inhibiteurs de thrombine
SI1311480T1 (sl) * 2000-08-16 2008-12-31 Astrazeneca Ab Novi amidino derivati in njihova uporaba kot trombinski inhibitorji
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation

Also Published As

Publication number Publication date
US20060014734A1 (en) 2006-01-19
UA82191C2 (uk) 2008-03-25
PL373908A1 (en) 2005-09-19
EP1513496A1 (fr) 2005-03-16
ZA200409237B (en) 2005-07-14
IL165069A0 (en) 2005-12-18
AR039935A1 (es) 2005-03-09
CA2485533A1 (fr) 2003-12-11
NO20044810L (no) 2005-02-24
NZ536739A (en) 2006-10-27
MXPA04011943A (es) 2005-03-31
JP4537197B2 (ja) 2010-09-01
TW200400940A (en) 2004-01-16
SG172473A1 (en) 2011-07-28
CL2008003324A1 (es) 2009-03-06
RU2004133387A (ru) 2005-07-10
IS7582A (is) 2004-12-03
TW200735864A (en) 2007-10-01
RU2351314C2 (ru) 2009-04-10
AU2003241239A1 (en) 2003-12-19
KR20050010016A (ko) 2005-01-26
JP2005536471A (ja) 2005-12-02
RU2008141850A (ru) 2010-04-27
CN1655760A (zh) 2005-08-17
AU2010200821A1 (en) 2010-03-25
TWI311555B (en) 2009-07-01
WO2003101423A1 (fr) 2003-12-11
JP2010209090A (ja) 2010-09-24
SA03240403B1 (ar) 2008-12-23
AU2003241239B2 (en) 2010-03-18
BR0311363A (pt) 2005-03-01

Similar Documents

Publication Publication Date Title
SE0201659D0 (sv) Modified release pharmaceutical formulation
SE0201658D0 (sv) Immediate release pharmaceutical formulation
TNSN03110A1 (fr) Azaindoles.
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
SE0202463D0 (sv) Novel compounds
UA74391C2 (uk) Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти
GB0005357D0 (en) Compounds
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
CY1110593T1 (el) Η χρηση φαρμακευτικης συνθεσης που περιεχει παραγωγο παρα - αμινοφαινυλοξικου οξεος για τη θεραπεια των φλεγμονωδων καταστασεων του γαστρεντερικου σωληνα
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
EP1340755A4 (fr) Agents de traitement des infections a helicobacter
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE337827T1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
BG106520A (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
MX9206930A (es) Nuevos compuestos
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
DK601983A (da) Aminoethoxybenzylalkoholderivater
MXPA05004842A (es) Formulacion oromucosal y proceso para su preparacion.